Targeted therapies in cancer : myth or reality?
著者
書誌事項
Targeted therapies in cancer : myth or reality?
(Advances in experimental medicine and biology, v. 610)
Springer, c2008
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Billions of dollars are spent every year on research into targeted therapies for cancer. That's why it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality.
目次
Causality in Medicine.- The Evolution of the Biomedical Paradigm in Oncology: Implications for Cancer Therapy.- Anticancer Drug Discovery and Development.- Beyond VEGF: Targeting Tumor Growth and Angiogenesis via Alternative Mechanisms.- Aurora Kinases and Their Inhibitors: More Than One Target and One Drug.- Signalling Pathways and Adhesion Molecules as Targets for Antiangiogenesis Therapy in Tumors.- Developing T-Cell Therapies for Cancer in an Academic Setting.- Anticancer Cell Therapy with TRAIL-Armed CD34+ Progenitor Cells.- Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies.- Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?.- GIST As the Model of Paradigm Shift Towards Targeted Therapy of Solid Tumors: Update and Perspective on Trial Design.- Monoclonal Antibodies in the Treatment of Malignant Lymphomas.- Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy.
「Nielsen BookData」 より